中國萬天控股(01854.HK)訂立銷售框架協議 料總金額不少於3,300萬美元
中國萬天控股(01854.HK)公布,其間接全資附屬公司豐源與獨立第三方訂立銷售框架協議。根據銷售框架協議,豐源將於今日至2024年12月12日期間向該客戶銷售6.5萬噸原產來自巴西的精制白砂糖。該客戶將按月訂立約5,000噸白糖的不可撤銷採購訂單,預計銷售框架協議的總金額約不少於3,300萬美元,惟視乎定期協商調整白糖價格而定。同時,豐源將與本地一間成立超過三十年的糖類大型批發商簽訂合作框架協議,提供源頭資源,以順利完成銷售目標。
董事會認為,訂立銷售框架協議將有助於集團在日常業務過程中拓展新的業務範圍,提升集團的收入及盈利能力,此乃符合集團業務發展策略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.